Clinical Trials Logo

Esophagus Disorder clinical trials

View clinical trials related to Esophagus Disorder.

Filter by:
  • None
  • Page 1

NCT ID: NCT06313060 Not yet recruiting - Esophagus Disorder Clinical Trials

Efficacy of Carbonated Beverages in the Resolution of Alimentary Esophageal Impaction

Start date: March 15, 2024
Phase: N/A
Study type: Interventional

Objectives: To evaluate the efficacy of the administration of carbonated beverages in the resolution of dietary esophageal impaction, and to identify subgroups in which their effectiveness may be different: patients with/without esophageal diseases, with/without a history of impaction. Methods: A clinical trial was conducted randomizing consecutive patients with a clinical diagnosis of dietary esophageal impaction to receive 200cc of carbonated drink or not at all, excluding patients with a previous diagnosis of non-esophageal stenosis that could not be overcome with a gastroscope and suspected impaction by non-alimentary foreign bodies, spines or bones. Subsequently, an endoscopic evaluation will be carried out in all cases, checking the presence or absence of a foreign body and removing it if necessary, as well as assessing and recording the possible underlying esophageal pathology. A telephone follow-up will be carried out after 7 days, recording possible adverse events.

NCT ID: NCT05204901 Completed - Clinical trials for Gastrointestinal Diseases

Using Magnetic Field Tracking to Confirm Nasogastric Tube Placement at Point of Care

Start date: May 4, 2022
Phase: N/A
Study type: Interventional

This is a trial on the feasibility of magnetic tracking for the confirmation of nasogastric tube location in human patients.

NCT ID: NCT03944863 Completed - Clinical trials for Esophageal Achalasia

Impact of Antibiotic Prophylaxis in Per-oral Endoscopic Myotomy for Esophageal Motor Disorders

Start date: December 2013
Phase:
Study type: Observational

No recommendation regarding antibiotic prophylaxis and preparation modalities are available for patients with esophageal motor disorders who benefit from Per-Oral Endoscopic Myotomy (POEM). The aim of our study was to evaluate the impact of antibiotic prophylaxis on the POEM's safety. This study was a comparative and multicentric retrospective analysis of a database prospectively maintained. Patients over 18 year's old with esophageal motor disorders confirmed by prior manometry, who underwent POEM were included. The primary endpoint was the occurrence of complications, as classified by Cotton, based on whether or not antibiotic prophylaxis was administered.

NCT ID: NCT03518905 Recruiting - Esophagus Disorder Clinical Trials

Radiofrequency Ablation for the Treatment of Large Symptomatic Heterotopic Gastric Mucosa

RAGE
Start date: April 16, 2018
Phase: N/A
Study type: Interventional

The heterotopic gastric mucosa found in the cervical esophagus was first described in 1805 and affects 10-15% of individuals undergoing esophagogastroduodenoscopy. It leads to laryngopharyngeal reflux (LPR), which causes symptoms like globus sensation, hoarseness and chronic cough. The Reflux Symptom Index (RSI) that ranges from 0-45 measures LPR. Scores greater than 13 are considered to be pathologic. Currently, patients that suffer from symptoms of LPR and present with a heterotopic gastric mucosa are routinely offered radiofrequency ablation (RFA) as curative treatment. Up to now, around 40 patients were already treated at the department of Surgery with 90% histologic eradication rates after 2 treatment sessions and no reported serious adverse event. Nevertheless, the placebo effect could also be responsible for perception of improving symptoms. Therefore, this prospective sham-controlled trial was designed to exclude the placebo effect. As the device is already approved and routinely used for focal ablation safety data are already available. Up to now, there were no major adverse events, whereas only 10% of patients describe a sensation of irritated throat that dissolves within the first three days after treatment.

NCT ID: NCT03108898 Completed - Esophagus Disorder Clinical Trials

Progenitor Cells in Human Esophagus

Start date: June 29, 2017
Phase:
Study type: Observational

The purpose of this study is to better understand how esophageal cells change with age.

NCT ID: NCT02998606 Terminated - Esophagus Disorder Clinical Trials

Movantik for Opioid-Related Esophageal Disorders

Start date: January 2017
Phase: Phase 2
Study type: Interventional

To date, few studies have assessed the effect of opioids on esophageal motility, mostly assessed the effect of single-dose intravenous morphine on esophageal motility. Recently a large retrospective study assessing the effect of opioids on esophageal motility found that esophageal motor dysfunction are common in chronic opioid users whether studied on opioids and off opioids. In addition, current opioid users also had significantly higher integrated relaxation pressure and manometric patterns consistent with type III achalasia. (Ratuapli 2015) Peripherally acting mu opioid receptor antagonists (PAMORA) appear to be useful to reduce the peripheral effects of mu opioid receptor agonists to delay gastrointestinal transit without affecting the centrally mediated analgesic effects. MOVANTIK™ (Naloxegol) is the first oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation. MOVANTIK™ (Naloxegol) has been recently approved for opioid-induced constipation. Given orally, 25 mg daily it improves symptoms of constipation. At this dose, MOVANTIK™ (Naloxegol) is effective and safe, with a limited side effect profile and is associated with preservation of centrally mediated analgesia. This study will explore the safety and tolerability of MOVANTIK™ (Naloxegol) in this patient population. The investigational hypothesis is that MOVANTIK™ (Naloxegol) could improve opioid- induced esophageal motility disorders